Abstract Number: 0822 • ACR Convergence 2021
Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
Background/Purpose: Adalimumab (ADL) can be self-administered every 2 weeks as a subcutaneous (s.c.) injection in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis…Abstract Number: 0944 • ACR Convergence 2021
A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease
Background/Purpose: Psoriasis (PsO) is an inflammatory, immune-mediated skin disorder affecting ~3% of the population worldwide. It is associated with multiple comorbidities, including psoriatic arthritis (PsA),…Abstract Number: 1781 • ACR Convergence 2021
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA) and contribute to unnecessary impairments in quality of life and function. Screening surveys for identifying at-risk…Abstract Number: 1784 • ACR Convergence 2021
Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry
Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention…Abstract Number: 1798 • ACR Convergence 2021
The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
Background/Purpose: Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis (PsO), and usually follows the development of PsO by an average of…Abstract Number: 0049 • ACR Convergence 2021
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…Abstract Number: 0053 • ACR Convergence 2021
Susceptibility Factors for Psoriatic Arthritis Single-cell RNA-Sequencing of Patients with Psoriatic Disease
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of patients with psoriasis. Thus, early diagnosis of this subgroup is crucial to…Abstract Number: 0054 • ACR Convergence 2021
TCR Immune Profiling of Patients with Psoriatic Disease
Background/Purpose: CD8+ and CD4+ T cell subsets have been implicated in the pathogenesis of psoriatic disease. Here, we explore the T-cell repertoire in psoriatic disease…Abstract Number: 0140 • ACR Convergence 2021
Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis
Background/Purpose: An interdisciplinary approach involving dermatologists and rheumatologists is required for the management of patients with psoriatic arthritis (PsA). The purpose of our study was…Abstract Number: 0241 • ACR Convergence 2021
Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
Background/Purpose: Paradoxical psoriasis has been increasingly reported in adults after exposure to tumor necrosis factor inhibitors (TNFi). Systematic studies in the pediatric population are lacking.…Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…Abstract Number: 823 • 2019 ACR/ARP Annual Meeting
The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…Abstract Number: 2463 • 2019 ACR/ARP Annual Meeting
Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis
Background/Purpose: Obesity is a leading comorbidity in both psoriasis (Pso) and psoriatic arthritis (PsA) and is associated with common metabolic complications and increased cardiovascular (CV)…Abstract Number: 1008 • 2019 ACR/ARP Annual Meeting
C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Background/Purpose: We previously identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between psoriasis arthritis (PsA) and psoriasis patients without arthritis (PsC). This study aimed…
- 1
- 2
- 3
- …
- 8
- Next Page »